Literature DB >> 11738306

Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery.

J X Qin1, T Shiota, H M Lever, S R Kapadia, M Sitges, D N Rubin, F Bauer, N L Greenberg, D A Agler, J K Drinko, M Martin, E M Tuzcu, N G Smedira, B Lytle, J D Thomas.   

Abstract

OBJECTIVES: This study was conducted to evaluate follow-up results in patients with hypertrophic obstructive cardiomyopathy (HOCM) who underwent either percutaneous transluminal septal myocardial ablation (PTSMA) or septal myectomy.
BACKGROUND: Controversy exists with regard to these two forms of treatment for patients with HOCM.
METHODS: Of 51 patients with HOCM treated, 25 were treated by PTSMA and 26 patients via myectomy. Two-dimensional echocardiograms were performed before both procedures, immediately afterwards and at a three-month follow-up. The New York Heart Association (NYHA) functional class was obtained before the procedures and at follow-up.
RESULTS: Interventricular septal thickness was significantly reduced at follow-up in both groups (2.3 +/- 0.4 cm vs. 1.9 +/- 0.4 cm for septal ablation and 2.4 +/- 0.6 cm vs. 1.7 +/- 0.2 cm for myectomy, both p < 0.001). Estimated by continuous-wave Doppler, the resting pressure gradient (PG) across the left ventricular outflow tract (LVOT) significantly decreased immediately after the procedures in both groups (64 +/- 39 mm Hg vs. 28 +/- 29 mm Hg for PTSMA, 62 +/- 43 mm Hg vs. 7 +/- 7 mm Hg for myectomy, both p < 0.0001). At three-month follow-up, the resting PG remained lower in the PTSMA and myectomy groups (24 +/- 19 mm Hg and 11 +/- 6 mm Hg, respectively, vs. those before procedures, both p < 0.0001). The NYHA functional class was also significantly improved in both groups (3.5 +/- 0.5 vs. 1.9 +/- 0.7 for PTSMA, 3.3 +/- 0.5 vs. 1.5 +/- 0.7 for myectomy, both p < 0.0001).
CONCLUSIONS: Both myectomy and PTSMA reduce LVOT obstruction and significantly improve NYHA functional class in patients with HOCM. However, there are benefits and drawbacks for each therapeutic method that must be counterbalanced when deciding on treatment for LVOT obstruction.

Entities:  

Keywords:  NASA Discipline Cardiopulmonary; Non-NASA Center

Mesh:

Year:  2001        PMID: 11738306     DOI: 10.1016/s0735-1097(01)01656-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  21 in total

Review 1.  Alcohol septal ablation for obstructive hypertrophic cardiomyopathy.

Authors:  Charles J Knight
Journal:  Heart       Date:  2006-09       Impact factor: 5.994

2.  Increasing evidence for the safety and efficacy of alcohol septal ablation during medium- and long-term follow-up.

Authors:  M Pauschinger; A Keren
Journal:  Clin Res Cardiol       Date:  2007-11-05       Impact factor: 5.460

3.  One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response.

Authors:  L Faber; D Welge; D Fassbender; H K Schmidt; D Horstkotte; H Seggewiss
Journal:  Clin Res Cardiol       Date:  2007-09-25       Impact factor: 5.460

4.  Effects of exercise on the duration of diastole and on interventricular phase differences in patients with hypertrophic cardiomyopathy: relationship to cardiac output reserve.

Authors:  Gunnar Plehn; Julia Vormbrock; Axel Meissner; Hans-Joachim Trappe
Journal:  J Nucl Cardiol       Date:  2009-01-22       Impact factor: 5.952

Review 5.  Hypertrophic cardiomyopathy: diagnosis, risk stratification and treatment.

Authors:  Daniel L Jacoby; Eugene C DePasquale; William J McKenna
Journal:  CMAJ       Date:  2012-10-29       Impact factor: 8.262

Review 6.  Management of hypertrophic cardiomyopathy in children.

Authors:  Hubert Seggewiss; Angelos Rigopoulos
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

7.  The Brockenbrough-Braunwald-Morrow sign.

Authors:  Alejandro R Trevino; John Buergler
Journal:  Methodist Debakey Cardiovasc J       Date:  2014 Jan-Mar

8.  Microvascular permeability changes might explain cardiac tamponade after alcohol septal ablation for hypertrophic cardiomyopathy.

Authors:  Jen-Te Hsu; Ju-Feng Hsiao; Jung-Jung Chang; Chang-Min Chung; Shih-Tai Chang; Kuo-Li Pan
Journal:  Tex Heart Inst J       Date:  2014-04-01

9.  Incidence of Atrial Fibrillation following Alcohol Septal Ablation for Hypertrophic Cardiomyopathy.

Authors:  Travis J Moss; Matthew M Zipse; Mori J Krantz; William H Sauer; Ernesto E Salcedo; Joseph L Schuller
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-03-11       Impact factor: 1.468

10.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy.

Authors:  Hicham El Masry; Jeffrey A Breall
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.